India, Sept. 28 -- Sun Pharmaceutical Industries Ltd has entered into an exclusive agreement with US-based LIB Therapeutics to manufacture, commercialise and globally license Lerodalcibep in all markets outside the United States and China.
Lerodalcibep is a once-monthly PCSK9 inhibitor used to lower low-density lipoprotein cholesterol (LDL-C) and treat adults with hypercholesterolaemia and mixed dyslipidaemia.
PCSK9 inhibitors are a class of medicines that help reduce levels of LDL, commonly referred to as "bad" cholesterol, by blocking the PCSK9 protein.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....